Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 277

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 277
---
 requirement but will not count as a vote cast at the Special Meeting. A broker non-vote will neither be counted towards the quorum requirement (as we believe the Adjournment Proposal will be considered as non-discretionary) nor count as a vote cast in the Special Meeting.

The Adjournment Proposal is not conditioned on the approval of any other proposal set forth in this proxy statement/prospectus.

#### Recommendation of the Iris Board

### THE IRIS BOARD UNANIMOUSLY RECOMMENDS THAT
<div align='center'>IRIS STOCKHOLDERS VOTE “FOR” THE ADJOURNMENT PROPOSAL.

136</div>

TABLE OF CONTENTS

### SHARES ELIGIBLE FOR FUTURE SALE
Upon completion of the Business Combination, ParentCo will have 500,000,000 shares of ParentCo Common Stock authorized and, based on the assumptions set out elsewhere in this proxy statement/ prospectus, up to 26,774,477 shares of ParentCo Common Stock issued and outstanding. Subject to the Amended and Restated Registration Rights Agreement and Lock-up Agreement discussed below, all of the shares of ParentCo Common Stock issued in connection with the Business Combination will be freely transferable by persons other than by ParentCo’s and Iris’s “affiliates” without restriction or further registration under the Securities Act. Sales of substantial amounts of ParentCo Common Stock in the public market could adversely affect prevailing market prices of the ParentCo Common Stock.

Amended and Restated Registration Rights Agreement

At the closing, ParentCo will enter into the Amended and Restated Registration Rights Agreement (the “RRA”) with Sponsor, Cantor, certain former members of Liminatus and the PIPE Investor with respect to the resale of 835,555 ParentCo Warrants exercisable for ParentCo Common Stock and up to 22,703,971 shares of ParentCo Common Stock. ParentCo will file a registration statement to register the public resale of the shares and warrants as soon as reasonably practicable, but in any event within 30 calendar days following the closing. In addition, subject to certain requirements and customary conditions, including with regard to the number of requests that may be made and when, the relevant stockholders may request to sell all or any portion of their registrable securities in an underwritten offering so long as the total offering price is reasonably expected to exceed, in the aggregate, $10 million. The RRA also provides certain demand rights and piggyback rights to ParentCo stockholders,